Persistence of education and monitoring is crucial to optimal gout management Save

Optimal gout care is dependent on having a well-informed health care provider who recognizes and follows the American College of Rheumatology gout management recommendations. It is important that the misconceptions and myths held by the patient are discussed and dispelled and, most importantly, establish a clear understanding of “the plan” and the reason for initiating urate-lowering therapy (ULT). The patient-provider discussion should include the reasons for lowering serum urate levels to below 6.0 mg/dL, and ensure patients know and track their urate level. Equally important for the patient’s success is that they need to remember they will need to remain on ULT for their lifetime. 

The latter message is frequently lost in the early stages of gout treatment when controlling pain and optimizing medication dosage are the primary focus. Most gout patients who receive a ULT prescription take it as directed early on in their treatment course but frequently discontinue treatment even before the target serum urate level is achieved. While there is a definite need for more in-depth communication and education between the patient and physician regarding gout, involving the patient in close monitoring of their serum urate levels is paramount.

Several clinical studies have demonstrated just how important this level of involvement can be. A large rheumatology practice in South Korea conducted an eight-year cohort study monitoring the rate of persistence of gout patients newly started on a xanthine oxidase inhibitor (XOI) (Kim et al Clinical Rheum 2020). The patients were all seen initially by the rheumatologists who emphasized important components of gout pathophysiology, potential risk factors and the expected clinical consequences of treatment. This initial exchange lasted approximately 45 minutes. The gout patients were then placed on either allopurinol or febuxostat and followed for up to eight years using their usual gout care treatment plans, but with no further specific educational efforts. Over time, the persistence rates for both allopurinol and febuxostat fell dramatically for the entire cohort and by the end of the first year, adherence was down to 67%. By five years, it was down to 40%. 

After the conclusion of the study, the investigators went back to patients who had discontinued their XOI therapy to determine the reasons. Despite the initial educational course, the patients reported persistent low healthcare literacy regarding gout, as well as poor understanding of the overall plan, as their leading reasons for discontinuation. 

The effectiveness of long-term educational activity and persistent engagement between the patient and physician was demonstrated by Rees, Doherty and their colleagues from Nottingham, U.K. This approach included an initial educational activity describing the causes of hyperuricemia and gout and review of permanent gout management guidelines and lifestyle recommendations, the discussion of illness perceptions and monitoring serum urate and creatinine. All of this was overseen by the clinic nurse, who was also in charge of monthly follow up telephone calls to discuss any problems with treatment adherence, dose adjustments, monitoring serum urate levels and scheduling a follow up phone call in a month's time. This pattern was repeated monthly until the patient achieved target serum urate levels; then phone calls were spread out every three months.

A dramatic improvement in the treat-to-target primary outcome was demonstrated in the first 12 months of follow-up, with 92% achieving a serum urate of less than 6.0 mg/dL and 85% reaching urate levels of less than 5.0 mg/dL.  The data for five-year follow-up was even more remarkable: 90% and 85% of patients remained at target for 6.0 and 5.0 mg/dL, respectively. 

This study, more than any other investigation of how to improve the historically poor adherence and persistence seen in gout treatment, has offered a blueprint. The Nottingham experience has shown us that when patients and providers stay engaged with each other for the long haul, the result is a lasting control of this destructive arthritis and its chronic inflammation.

Take home messages

1. Ongoing patient education and engagement are essential for successful gout management. Simply starting treatment isn’t enough. Patients need continuous education, clear understanding of their care plan, and regular follow-up to maintain adherence and achieve target urate levels.
2. Long-term adherence to urate-lowering therapy (ULT) is critical, but often lost without reinforcement. Many patients stop treatment early due to poor understanding, but consistent monitoring and provider–patient communication dramatically improve long-term outcomes and disease control.